van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M
PARP inhibition: PARP1 and beyond
Given that retatrutide is not currently licensed in the UK, the circumstances under which a patient might legitimately encounter this compound are limited primarily through participation in an approved clinical trial
The TRIUMPH Phase 3 program The TRIUMPH program consists of multiple Phase 3 trials evaluating retatrutide in different populations
(Sartain, 2024) A study found that tapering patients off of semaglutide over a course of 9 weeks while being coached on diet and exercise led to sustainable weight management after being off of the medication for 26 weeks
Contact your healthcare provider if you experience minimal improvement after reaching maintenance dose for 12-16 weeks, including persistently elevated blood glucose or lack of at least 5% body weight reduction